Most Likely Cause: Rivaroxaban (Xarelto)
The cutaneous vasculitis rash in this octogenarian patient is most likely caused by rivaroxaban (Xarelto), which is a well-documented cause of leukocytoclastic vasculitis, even with negative ANCA titers. 1, 2
Primary Culprit: Direct Oral Anticoagulants
Rivaroxaban is the most probable offender based on:
- Direct case evidence: Multiple published cases specifically document rivaroxaban-induced leukocytoclastic vasculitis (LCV) 1, 2
- Mechanism: Novel oral anticoagulants (NOACs) can trigger cutaneous LCV through immune complex formation, neutrophil apoptosis induction, and neoantigen formation between the drug and host proteins 3
- Clinical pattern: The vasculitis typically presents as palpable purpura on lower extremities, which matches the description of "cutaneous vasculitis rash" 1, 2
- ANCA-negative presentation: Importantly, rivaroxaban-induced vasculitis often presents with negative ANCA titers, which is unusual for drug-induced vasculitis but well-documented with this medication 1
Secondary Considerations
Other Medications to Consider:
Torsemide (loop diuretic): While less commonly reported, diuretics can occasionally cause drug-induced vasculitis 4. However, this is far less likely than rivaroxaban.
Atorvastatin (Lipitor): Can cause drug eruptions and rashes 5, but these typically present as maculopapular eruptions or dermatitis rather than true vasculitis. The rash pattern described is inconsistent with statin-induced reactions.
Farxiga (dapagliflozin): The FDA label mentions "rash" as a postmarketing adverse reaction 6, and hypersensitivity reactions including urticaria have been reported. However, true cutaneous vasculitis is not documented with SGLT2 inhibitors in the provided evidence.
Other medications (aspirin, carvedilol, ezetimibe, pregabalin): These are unlikely culprits for cutaneous vasculitis based on their adverse effect profiles.
Diagnostic Approach
To confirm rivaroxaban as the cause:
- Temporal relationship: Determine when rivaroxaban was started relative to rash onset (hours to years is possible 4)
- Skin biopsy: Should show leukocytoclastic vasculitis with neutrophilic infiltration of vessel walls 1, 2
- Laboratory exclusions:
- ANCA titers (expect negative with rivaroxaban) 1
- Complement levels (C3, C4, CH50 - expect normal)
- Hepatitis C, HIV, Lyme disease (to exclude infectious causes)
- Cryoglobulins if systemic involvement suspected
Management Algorithm
Immediate action: Discontinue rivaroxaban 1, 2, 3
Anticoagulation alternative: Switch to warfarin, which has been successfully used after rivaroxaban-induced vasculitis 1. Apixaban should be avoided as cross-reactivity between NOACs has been reported 1.
Symptomatic treatment:
- Mild cases: Drug discontinuation alone may suffice 3
- Moderate to severe cases: Short course of systemic corticosteroids 1, 3
- Life-threatening/systemic involvement: Consider plasmapheresis, cyclophosphamide, or IVIG 4, 7
Critical Pitfalls to Avoid
⚠️ Do not rechallenge with rivaroxaban or switch to apixaban, as cross-reactivity between NOACs is documented 1
⚠️ Do not delay discontinuation while awaiting biopsy results - drug-induced vasculitis can progress to multi-organ involvement with 10% mortality in severe cases 4
⚠️ Do not assume ANCA-positive disease - rivaroxaban-induced vasculitis characteristically presents with negative ANCA titers 1
⚠️ Monitor for systemic involvement: Check renal function, urinalysis, and assess for pulmonary or GI symptoms, as drug-induced vasculitis can affect multiple organ systems 4, 7
Prognosis
Drug-induced cutaneous vasculitis typically has excellent prognosis when the offending agent is discontinued promptly 3. Most cases resolve within weeks of drug withdrawal, though some may require a short steroid course 1, 3. This contrasts with idiopathic vasculitis, which requires prolonged immunosuppression.